Marinus Pharma (NASDAQ: MRNS) reported Q2 EPS of ($0.63), $0.04 worse than the analyst estimate of ($0.59). Revenue for the quarter came in at $8.06 million versus the consensus estimate of $9.5 million.

GUIDANCE:

Marinus Pharma sees FY2024 revenue of $33-35 million, versus the consensus of $39.35 million.

For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.